Josee Cote
Overview
Explore the profile of Josee Cote including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
565
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Robbins J, Tait D, Huang Q, Dubey S, Crumley T, Cote J, et al.
EBioMedicine
. 2022 Jul;
82:104138.
PMID: 35809371
Background: Vaccines against COVID-19 are needed to overcome challenges associated with mitigating the global pandemic. We report the safety and immunogenicity of V590, a live recombinant vesicular stomatitis virus-based COVID-19...
2.
Vachal P, Duffy J, Campeau L, Amin R, Mitra K, Murphy B, et al.
J Med Chem
. 2021 Aug;
64(18):13215-13258.
PMID: 34375108
Cholesteryl ester transfer protein (CETP) represents one of the key regulators of the homeostasis of lipid particles, including high-density lipoprotein (HDL) and low-density lipoprotein (LDL) particles. Epidemiological evidence correlates increased...
3.
Krishna R, Gheyas F, Corr C, Cote J, Liu Y, Wagner J, et al.
J Clin Pharmacol
. 2018 Jul;
58(12):1578-1585.
PMID: 30029292
Anacetrapib is a cholesteryl ester transfer protein inhibitor intended for the treatment of dyslipidemia. A phase 1 study was conducted to examine the pharmacokinetics and pharmacodynamics of multiple doses of...
4.
Krishna R, Gheyas F, Liu Y, Cote J, Laterza O, Ruckle J, et al.
J Clin Pharmacol
. 2017 Sep;
58(2):254-262.
PMID: 28884824
Anacetrapib is a cholesteryl ester transfer protein (CETP) inhibitor being developed for the treatment of mixed dyslipidemia. The aim of the study was to evaluate the pharmacokinetic, pharmacodynamic, and safety...
5.
Lauring B, Li X, Liu Y, Corr C, Lazarus N, Cote J, et al.
J Clin Pharmacol
. 2014 May;
54(11):1247-55.
PMID: 24782116
Two open-label, parallel-group studies evaluated the influence of renal and hepatic insufficiency on the pharmacokinetics of a single-dose anacetrapib 100 mg. Eligible participants included adult men and women with moderate...
6.
Anderson M, Cote J, Liu Y, Stypinski D, Auger P, Hohnstein A, et al.
J Clin Pharmacol
. 2013 May;
53(7):746-52.
PMID: 23670789
Anacetrapib is a novel cholesteryl ester transfer protein (CETP) inhibitor in development for treatment of dyslipidemia. This open-label, fixed-sequence, 3-period study was intended to evaluate the potential of anacetrapib to...
7.
Gagnon J, Saint-Arnaud J, Bourdeau M, Cote J, Chapados C, Michaud C
Can J Aging
. 2012 Dec;
31(4):435-44.
PMID: 23234837
Unlabelled: The End-Stage Renal Disease population is aging. Considering that hemodialysis is a treatment that maintains and prolongs life, this descriptive-comparative study looks at the perceptions of patients according to...
8.
Lauring B, Taggart A, Tata J, Dunbar R, Caro L, Cheng K, et al.
Sci Transl Med
. 2012 Aug;
4(148):148ra115.
PMID: 22914621
Nicotinic acid (niacin) induces beneficial changes in serum lipoproteins and has been associated with beneficial cardiovascular effects. Niacin reduces low-density lipoprotein, increases high-density lipoprotein, and decreases triglycerides. It is well...
9.
Boatman P, Lauring B, Schrader T, Kasem M, Johnson B, Skinner P, et al.
J Med Chem
. 2012 Mar;
55(8):3644-66.
PMID: 22435740
G-protein coupled receptor (GPCR) GPR109a is a molecular target for nicotinic acid and is expressed in adipocytes, spleen, and immune cells. Nicotinic acid has long been used for the treatment...
10.
Krishna R, Stypinski D, Ali M, Garg A, Cote J, Maes A, et al.
Br J Clin Pharmacol
. 2012 Jan;
74(1):116-24.
PMID: 22243494
What Is Already Known About This Subject: • Inhibition of cholesteryl ester transfer protein (CETP) is a potential new mechanism for the treatment of dyslipidaemia. Anacetrapib is a novel CETP...